慢性疼痛临床试验中效益与危害的平衡评估:优先考虑个体参与者而非单一结局
该综述回顾了2016至2021年间6本主要疼痛期刊的73项慢性疼痛随机对照试验,发现仅2项使用了效益与危害的复合结局指标,且均为两种活性治疗比较。作者认为复合结局在慢性疼痛试验中利用不足,并讨论了其优势与挑战。
要点
- 慢性疼痛随机对照试验中效益与危害复合结局的使用率极低(73项中仅2项)。
- 复合结局可整合效益与安全性信息,更全面评估治疗整体效应。
- 复合结局可用于试验设计、数据安全监查委员会决策及治疗指南排序。
核心结论
- 慢性疼痛随机对照试验中效益与危害的复合结局指标使用不足。
研究设计与样本
- 证据综述:回顾2016至2021年发表于6本主要疼痛期刊的73项慢性疼痛随机对照试验。
主要发现
- 73项随机对照试验中仅2项包含效益与危害的复合结局指标。
- 该2项研究均比较两种活性治疗。
临床怎么用
- 在慢性疼痛随机对照试验中可考虑采用效益与危害复合结局,以更全面评估治疗整体效应。
- 复合结局可支持数据安全监查委员会的决策及治疗指南中的治疗排序。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Randomized clinical trials (RCTs) generally assess efficacy and safety separately, with the conclusion of whether a treatment is beneficial based solely on the efficacy endpoint. However, assessing and combining efficacy and safety domains, using a single composite outcome measure, can provide a more comprehensive assessment of the overall effect of a treatment. Furthermore, composite outcomes can incorporate information regarding the relationship between the individual outcomes. In fact, such outcomes have been suggested in the clinical trials literature for at least 15 years. OBJECTIVES: To (1) identify whether recent primary publications of chronic pain RCTs from major pain journals included a composite outcome measure of benefits and harms and (2) discuss the potential benefits of such outcomes in various stages of treatment development, including as outcome measures in RCTs, and to support decisions of Data and Safety Monitoring Boards and ordering of treatments in the context of treatment guidelines. EVIDENCE REVIEW: RCTs published in 6 major pain journals published between 2016 and 2021 that investigated interventions for chronic pain were reviewed. FINDINGS: Of 73 RCTs identified, only 2 included a composite outcome measure of benefits and harms. Both of these articles compared 2 active treatments. CONCLUSIONS: Composite outcomes of benefits and harms are underutilized in chronic pain RCTs. The advantages and challenges of using such outcomes are discussed.
引用
- Nishtar M, Mark R, Langford DJ, et al. Evaluating the balance of benefits and harms in chronic pain clinical trials: prioritizing individual participants over individual outcomes. Reg Anesth Pain Med. 2024. PMID: 37963675. doi:10.1136/rapm-2023-104809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。